zyprexa medication
Click on image below to visit zyprexa Online Page
M2 PRESSWIRE-27 February 2004-Research and Markets: Lilly’s Zyprexa is leading the bipolar market in terms of revenue and life cycle management, with recent approval for reformulation in a combination pill with Prozac as Symbyax(C)1994-2004 M2 COMMUNICATIONS LTD RDATE:02272004 Research and Markets are delighted to announce the addition of Stakeholder Insight: Bipolar Disorders - Zyprexa Sets the Mood for Revenue Growth to their offering.
According to a New York Times article published on December 17, 2006,[20] Eli Lilly has engaged in a decade-long effort to play down the health risks of Zyprexa, its best-selling medication for schizophrenia, according to hundreds of internal Lilly documents and e-mail messages among top company managers. These documents and e-mail messages were soon made publicly available as a location hidden Tor service[21], and then made available on the public Internet. Eli Lilly got a temporary restraining order from a US District Court signed on January 4, 2007 to stop the dissemination or downloading of Eli Lilly documents about Zyprexa, and this allowed them to get a few US-based websites to remove them; on January 8, 2007, Judge Jack B. Weinstein refused the Electronic Frontier Foundation’s motion to stay his order[22]. The documents can now only be downloaded from public Internet sites outside the US.[23][24][25]These health risks include an increased risk for diabetes through Zyprexa’s links to obesity and its tendency to raise blood sugar. Zyprexa is Lilly’s top-selling drug, with sales of $4.2 billion last year.
The documents, given to The New York Times by Jim Gottstein, a lawyer representing mentally ill patients, show that Lilly executives kept important information from doctors about Zyprexa’s links to obesity and its tendency to raise blood sugar — both known risk factors for diabetes. The Times of London also obtained copies of the documents and reported that as early as October 1998, Lilly considered the risk of drug-induced obesity to be a “top threat” to Zyprexa sales.[26] In another document, dated October 9, 2000, senior Lilly research physician Robert Baker noted that an academic advisory board he belonged to was “quite impressed by the magnitude of weight gain on olanzapine and implications for glucose.”
Lilly’s own published data, which it told its sales representatives to play down in conversations with doctors, has shown that 30 percent of patients taking Zyprexa gain 22 pounds or more after a year on the drug, another study showed 16% of Zyprexa patients gained at least 30kg (66 pounds) in one year, and some patients have reported gaining 100 pounds or more. But Lilly was concerned that Zyprexa’s sales would be hurt if the company was more forthright about the fact that the drug might cause unmanageable weight gain or diabetes, according to the documents, which cover the period 1995 to 2004. In 2006, Lilly paid $700 million to settle 8,000 lawsuits from people who said they had developed diabetes or other diseases after taking Zyprexa. Thousands more suits are still pending.[27]
In 2002, British and Japanese regulatory agencies warned that Zyprexa may be linked to diabetes, but even after the FDA issued a similar warning in 2003, Lilly did not publicly disclose their own findings.
Eli Lilly agreed on January 4, 2007 to pay up to $500 million to settle 18,000 lawsuits from people who claimed they developed diabetes or other diseases after taking Zyprexa. Including earlier settlements over Zyprexa, Lilly has now agreed to pay at least $1.2 billion to 28,500 people who claim they were injured by the drug. At least 1,200 suits are still pending, the company said. About 20 million people worldwide have taken Zyprexa since its introduction in 1996.[28]
Prozac zyprexa
Side effects of zyprexa
Heninger garrison davis zyprexa
Zyprexa injury
Overdose zyprexa
Litigation zyprexa
Zyprexa class action law suit